Benralizumab noninferior to mepolizumab for EGPA

IF 29.4 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2024-04-09 DOI:10.1038/s41584-024-01116-6

Sarah Onuora

引用次数: 0

Abstract

In a head-to-head phase III trial of two drugs that target IL-5 or its receptor, benralizumab was noninferior to mepolizumab for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis.

查看原文本刊更多论文

本拉珠单抗治疗 EGPA 的疗效不劣于麦泊珠单抗

在一项针对IL-5或其受体的两种药物的头对头III期试验中，在诱导嗜酸性粒细胞肉芽肿伴多血管炎患者病情缓解方面，benralizumab的疗效并不优于mepolizumab。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.